Loading...
Gut-targeted local effects vs systemic tissue repair — what the evidence actually supports for each route
BPC-157 is one of the most widely used peptides in the biohacking community, and the oral vs injectable debate generates more confusion than almost any other topic. Companies market oral capsules as a convenient alternative, while practitioners overwhelmingly recommend injection. The truth is more nuanced than either camp admits — but the nuance favors injection for the vast majority of use cases.
Oral peptide delivery faces three sequential barriers that each independently reduce bioavailability to near zero for systemic targets. Understanding these barriers is essential before evaluating any route comparison claims.
Sequential barriers to oral peptide absorption
This is the critical nuance most discussions miss. Some animal studies show that oral BPC-157 produces local effects on the gastrointestinal mucosa — ulcer healing, mucosal protection, reduced inflammation at the gut wall. These are contact effects, not evidence of systemic absorption. The peptide touches the gut lining and triggers local signaling before being degraded.
In Sikiric et al. (2018) and related rodent studies, oral BPC-157 demonstrated protective effects on gastric ulcers, inflammatory bowel lesions, and esophageal damage. These results are real — but they describe a topical effect on the GI tract, not systemic delivery. The peptide interacts with mucosal cells before enzymatic degradation destroys it. This is fundamentally different from the systemic tissue repair (tendon, joint, nerve, muscle) that most users are seeking.
| Systemic bioavailability | Oral: ~0% / Injectable: ~95-100% |
| Tendon and ligament repair | Oral: No evidence / Injectable: Strong animal evidence + practitioner consensus |
| Joint inflammation | Oral: No evidence / Injectable (local SubQ): Strong practitioner data |
| Gut mucosal healing (ulcers, IBD) | Oral: Some animal evidence for local contact effects / Injectable (abdominal SubQ): Strong evidence via systemic pathways |
| Neuroprotection | Oral: No evidence / Injectable: Moderate animal evidence |
| Dose range | Oral: 500-1000mcg (mostly degraded) / Injectable: 250-500mcg (fully bioavailable) |
| Cost efficiency | Oral: Poor — paying for peptide that gets destroyed / Injectable: High — full dose reaches target |
BPC-157 arginine salt (sometimes marketed as the 'stable oral form') was developed to improve acid stability. The arginine counterion does protect the peptide from pH-driven degradation in gastric acid. However, acid stability is only the first barrier — enzymatic degradation and epithelial impermeability remain unchanged. No published study has demonstrated meaningful systemic bioavailability from the arginine salt formulation in any species.
Dose
250 — 500mcg per day
Frequency
Once or twice daily
Route
Subcutaneous — near injury site for local repair, or abdominal SubQ for gut/systemic protocols
Mechanism: Full systemic bioavailability; promotes angiogenesis, growth factor upregulation, nitric oxide pathway modulation, and tissue repair signaling throughout the body
For gut-specific protocols (IBS, leaky gut, ulcers): abdominal subcutaneous injection is still recommended over oral. BPC-157 heals gut tissue through systemic signaling pathways — blood-borne delivery to the gut wall is more effective than degraded oral contact.
Log doses, monitor interactions, and optimize your stack with AI tools.
Open DoseCraftPharma-grade, third-party tested. Our preferred vendor for the DoseCraft community.
Shop Peptide PartnersInjectable BPC-157 is the evidence-supported route for every use case — systemic tissue repair, neuroprotection, gut healing, and inflammation reduction. The only theoretical niche for oral BPC-157 is direct mucosal contact in the upper GI tract (esophageal or gastric ulcers), and even there, injectable delivery via abdominal SubQ produces stronger results in the available animal data. For the overwhelming majority of users, oral BPC-157 capsules represent wasted money on a peptide that never reaches its target.
This article is for educational purposes only. Peptide regulations vary by jurisdiction. Always consult a licensed healthcare professional before starting any protocol.
Track your protocol with precision tools. Source pharma-grade compounds from a trusted vendor.
Build this protocol in 60 seconds. AI-powered dose logging, half-life tracking, and interaction checks.
Open Protocol BuilderPharma-grade, third-party tested peptides from our preferred vendor. Trusted by the community.
Shop Peptide PartnersOral BPC-157 capsules are marketed as a convenient alternative to injections, but the science is clear: proteolytic enzymes destroy the 15-amino-acid peptide before systemic absorption. Here's why subcutaneous injection is the only effective route.
Read researchA step-by-step guide to reconstituting peptides correctly. Covers bacteriostatic water vs sterile water selection, concentration math for accurate dosing, proper storage temperatures, and shelf life expectations for reconstituted peptides.
Read researchThe claim that BPC-157 causes cancer because it promotes angiogenesis is intellectually lazy and biologically uninformed. This article examines the actual mechanisms, the immune-supporting evidence, and why conflating angiogenesis with cancer promotion fails basic biological scrutiny.
Read researchNot medical advice — educational only. DoseCraft is an information and personal tracking platform. We do not provide medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting any protocol. Affiliate links may be present — we only recommend vendors we trust.